GlaxoSmithKline may exit the respiratory business and pull back in other areas to commit more cash to cancer R&D, according to Axel Hoos. Hoos, GSK’s head of oncology, ...
AstraZeneca, along with its global biologics research and development unit MedImmune, and German biotech Ethris have entered a strategic research collaboration to develop stabilised non-immunogenic modified messenger ribonucleic acid (mRNA) therapies for